Spots Global Cancer Trial Database for BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs
Official Title: BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs (BLOOD Trial)
Study ID: NCT04473027
Interventions
Study Description
Brief Summary: BLOOD is an investigator-initiated, multicenter, prospective biomarker study in patients with advanced melanoma treated with anti-PD-1 monotherapy in the first-line setting. The "studied products" will be administered and managed within routine medical care in Belgium. The overall goal is (i) to investigate biomarkers for anti-PD-1 monotherapy and (ii) to gather evidence on real-life use of anti-PD-1 monotherapy in melanoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Hospital Gent, Gent, , Belgium
Contact Details
Name: Hannelore Denys, MD, PhD
Affiliation: Medical Oncologist
Role: PRINCIPAL_INVESTIGATOR
Name: Emiel De Jaeghere, MD
Affiliation: PhD Fellow
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
